Forte Biosciences (FBRX) Shares Outstanding (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Shares Outstanding (Entity) of $17.8 million for Q1 2026, up 56.48% year-over-year from $11.4 million in Q1 2025, and up 37.76% quarter-over-quarter from $12.9 million in Q4 2025.
Forte Biosciences (FBRX) Shares Outstanding (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Shares Outstanding (Entity) for 11 consecutive years, with $17.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 56.48% year-over-year to $17.8 million; the TTM figure through Mar 2026 stood at $17.8 million (up 56.48% YoY), while the FY2025 annual figure was $12.9 million, up 344.06% from the prior year.
- Shares Outstanding (Entity) advanced to $17.8 million in Q1 2026 per FBRX's latest filing, from $12.9 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $17.8 million in Q1 2026 and bottomed at $590450.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $5.2 million across 5 years, with a median of $1.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) slumped 99.89% — and 2025, when it surged 863.06%.
- Forte Biosciences' Shares Outstanding (Entity) stood at $695341.0 in 2022, then jumped by 109.02% to $1.5 million in 2023, then surged by 100.63% to $2.9 million in 2024, then soared by 344.06% to $12.9 million in 2025, then soared by 37.76% to $17.8 million in 2026.
- Business Quant data shows FBRX's Shares Outstanding (Entity) at $17.8 million in Q1 2026, $12.9 million in Q4 2025, and $17.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 23.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.84 Mn |
| Mar 31, 2026 | 17.84 Mn |
| Dec 31, 2025 | 14.72 Mn |
| Sep 30, 2025 | 17.79 Mn |
| Jun 30, 2025 | 11.74 Mn |
| Mar 31, 2025 | 11.40 Mn |
| Dec 31, 2024 | 2.92 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 841,873.00 |
| Mar 31, 2023 | 840,267.00 |
| Dec 31, 2022 | 695,341.00 |
| Sep 30, 2022 | 757,098.00 |
| Jun 30, 2022 | 590,450.00 |
| Mar 31, 2022 | 590,392.00 |
| Dec 31, 2021 | 558,713.00 |
| Sep 30, 2021 | 569,649.00 |